SAN FRANCISCO (EGMN) - A new clinical tool that predicts a patient's risk for chemotherapy-associated venous thromboembolism also can forecast progression-free survival and overall survival, investigators reported at the annual meeting of the American Society of Hematology. Patients with scores showing high risk of venous thromboembolism (VTE) had worse survival outcomes, while those with low VTE risk fared better in a prospective study of more than 4,400 adults with various cancers. The researchers...